We know that both a positive family history and racial background are among the strongest epidemiological risk factors for prostate cancer. It is also recognized that the role of candidate genetic markers to prostate cancer is more difficult to identify than the identification of other cancer susceptibility genes. Despite the localization of several susceptibility loci, [...]
According to Bloomberg News Celgene Corp. said it will stop a study (Mainsail) of its blood-cancer pill Revlimid as a treatment for prostate cancer because the drug failed to help patients more than chemotherapy and steroids alone. This conclusion was drawn after the data-monitoring panel found the drug did not meet its primary goal of [...]
Amgen announced that they have published the results from their Phase 3 trial (the '147 study) that evaluated XGEVA® (denosumab) for use in preventing or delaying the onset of bone metastases in men with non-metastatic castration-resistant prostate cancer (CRPC). The results were published in The Lancet. The study found XGEVA significantly prolonged bone metastasis-free survival, [...]
Initially, when first used by Huggins and Hodges hormone therapy (ADT) was recommended to be used early on in prostate cancer disease progression. Eventually, the Veterans Administration Cooperative Urology Research Group (VACURG) studies reversed this early recommendation. After this study ADT was usually deferred until symptomatic progression. It was believed that ADT caused an alteration [...]
In today's issue of Cancer Discovery a group of international researchers report that an investigational drug had a dramatic response in animal models of neuroendocrine prostate cancer, a lethal form of the disease. The researchers pointed out that fewer than 2% of prostate tumors in men are initially diagnosed as neuroendocrine, but many of the [...]